ipamorelin safety human studies Risks of Unapproved Peptides for Health & Performance cjc-1295 ipamorelin clinical trials safety

Ipamorelin is the cleaner alternative

First characterised in receptor pharmacology studies published in the late 1990s (DOI 10.1046/j.1365-2265.1998.00629.x), ipamorelin was specifically designed to improve on the selectivity limitations of earlier GHRPs such as GHRP-2 and hexarelin, both of which produced meaningful elevations of cortisol and prolactin alongside GH stimulation

Selective Receptor Targeting Ipamorelin is studied for its specificity in receptor interaction models

Sustainable fat loss represents one of the most sought-after benefits, with many patients experiencing significant reductions in body fat percentage while maintaining or increasing lean muscle mass